Chi Sheng Chemical (4111) - Net Assets
Based on the latest financial reports, Chi Sheng Chemical (4111) has net assets worth NT$1.29 Billion TWD (≈ $40.68 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.84 Billion ≈ $58.01 Million USD) and total liabilities (NT$550.20 Million ≈ $17.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Chi Sheng Chemical's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.29 Billion |
| % of Total Assets | 70.12% |
| Annual Growth Rate | 2.76% |
| 5-Year Change | 18.48% |
| 10-Year Change | N/A |
| Growth Volatility | 3.77 |
Chi Sheng Chemical - Net Assets Trend (2017–2024)
This chart illustrates how Chi Sheng Chemical's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Chi Sheng Chemical worth.
Annual Net Assets for Chi Sheng Chemical (2017–2024)
The table below shows the annual net assets of Chi Sheng Chemical from 2017 to 2024. Also explore Chi Sheng Chemical (4111) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.27 Billion ≈ $40.16 Million |
+4.55% |
| 2023-12-31 | NT$1.22 Billion ≈ $38.41 Million |
-0.25% |
| 2022-12-31 | NT$1.22 Billion ≈ $38.50 Million |
+11.03% |
| 2021-12-31 | NT$1.10 Billion ≈ $34.68 Million |
+2.32% |
| 2020-12-31 | NT$1.08 Billion ≈ $33.89 Million |
+0.37% |
| 2019-12-31 | NT$1.07 Billion ≈ $33.77 Million |
+2.55% |
| 2018-12-31 | NT$1.05 Billion ≈ $32.93 Million |
-0.80% |
| 2017-12-31 | NT$1.05 Billion ≈ $33.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chi Sheng Chemical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$401.26 Million | 31.48% |
| Other Components | NT$873.29 Million | 68.52% |
| Total Equity | NT$1.27 Billion | 100.00% |
Chi Sheng Chemical Competitors by Market Cap
The table below lists competitors of Chi Sheng Chemical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
$54.14 Million |
|
Regis Corporation Common Stock
NYSE:RGS
|
$54.20 Million |
|
Inspirato Inc
NASDAQ:ISPO
|
$54.21 Million |
|
PP Properti Tbk PT
JK:PPRO
|
$54.21 Million |
|
Integrated Logistics Bhd
KLSE:5614
|
$54.07 Million |
|
Remed Co.Ltd
KQ:302550
|
$54.06 Million |
|
Daewon Media Co. Ltd
KQ:048910
|
$54.05 Million |
|
GP Global Power Ltd
TA:GPGB
|
$54.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chi Sheng Chemical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,219,061,000 to 1,274,550,000, a change of 55,489,000 (4.6%).
- Net income of 110,633,000 contributed positively to equity growth.
- Dividend payments of 56,983,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$110.63 Million | +8.68% |
| Dividends Paid | NT$56.98 Million | -4.47% |
| Other Changes | NT$1.84 Million | +0.14% |
| Total Change | NT$- | 4.55% |
Book Value vs Market Value Analysis
This analysis compares Chi Sheng Chemical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.55x to 1.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$18.49 | NT$28.70 | x |
| 2018-12-31 | NT$18.34 | NT$28.70 | x |
| 2019-12-31 | NT$18.73 | NT$28.70 | x |
| 2020-12-31 | NT$18.80 | NT$28.70 | x |
| 2021-12-31 | NT$19.22 | NT$28.70 | x |
| 2022-12-31 | NT$21.32 | NT$28.70 | x |
| 2023-12-31 | NT$20.37 | NT$28.70 | x |
| 2024-12-31 | NT$21.30 | NT$28.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chi Sheng Chemical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.68%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.49%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.37x
- Recent ROE (8.68%) is above the historical average (7.29%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 7.76% | 7.83% | 0.70x | 1.41x | NT$-23.61 Million |
| 2018 | 4.04% | 4.37% | 0.64x | 1.44x | NT$-62.26 Million |
| 2019 | 6.76% | 7.08% | 0.67x | 1.42x | NT$-34.73 Million |
| 2020 | 5.50% | 6.04% | 0.66x | 1.38x | NT$-48.44 Million |
| 2021 | 7.34% | 7.90% | 0.62x | 1.51x | NT$-29.32 Million |
| 2022 | 12.60% | 13.47% | 0.63x | 1.47x | NT$31.79 Million |
| 2023 | 5.63% | 6.47% | 0.60x | 1.45x | NT$-53.23 Million |
| 2024 | 8.68% | 9.49% | 0.67x | 1.37x | NT$-16.82 Million |
Industry Comparison
This section compares Chi Sheng Chemical's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,286,842,556
- Average return on equity (ROE) among peers: 12.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chi Sheng Chemical (4111) | NT$1.29 Billion | 7.76% | 0.43x | $54.10 Million |
| St.Shine Optical Co Ltd (1565) | $612.78 Million | 17.93% | 0.32x | $152.17 Million |
| Maxigen Biotech Inc (1783) | $369.25 Million | -9.77% | 0.32x | $102.44 Million |
| SciVision Biotech Inc (1786) | $1.45 Billion | 7.02% | 0.56x | $97.91 Million |
| Bioteque (4107) | $1.25 Billion | 12.65% | 0.38x | $242.34 Million |
| BenQ Medical Technology (4116) | $1.12 Billion | 5.55% | 0.61x | $55.39 Million |
| Pacific Hospital Supply Co Ltd (4126) | $1.35 Billion | 25.50% | 0.22x | $177.95 Million |
| Bionime Corp (4737) | $1.07 Billion | 8.40% | 3.23x | $145.36 Million |
| Vizionfocus Inc. (4771) | $2.04 Billion | 27.62% | 1.19x | $381.03 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.32 Billion | 13.08% | 0.82x | $170.87 Million |
About Chi Sheng Chemical
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic … Read more